ONE SIMPLE MOVE NOW—make the move to ONE-dose convenience for 24-hour, continuous dopamine stimulation.
Noncompliance With PD Medications Is High CASE PROFILE—GLEN, WANTS A SIMPLER PD MEDICATION
•
55 years of age
•
Hoehn and Yahr stage II (diagnosed 2 years ago)
•
Very active, works full time
•
eceiving 9 mg immediateR release ropinirole and L-dopa
•
Has admitted to skipping or forgetting to take his afternoon dose
Once-Daily REQUIP XL 24-hour Extended-Release Formulation for Continuous Dopamine Stimulation
Unique 3-layer tablet extends the rate, location, and timing of ropinirole release, allowing for convenient once-daily dosing
Plasma Concentration Over Time: REQUIP XL 24-hour and IR Ropinirole CONVERT FROM IR ROPINIROLE TO REQUIP XL 24-HOUR
0.7
A Third of Patients Are Noncompliant in the First Year of Treatment Rate of Nonadherence With PD Medications by Duration of Follow-Up
Rate of nonadherence
57%
REQUIP plasma concentration (ng/mL)
TREATMENT STRATEGY
0.6 0.5 0.4 0.3 0.2 IR ropinirole REQUIP XL 24-hour
0.1 0
50%
0
4
8
12
16
20
Time after dosing (hours)
43%
• Avoids peaks and troughs associated with immediate-release DAs • Achieves steady-state concentrations of ropinirole within 4 days of dosing
32%
Dosing Simplicity Leads to Compliance 12 Months
24 Months
36 Months
48 Months
Retrospective analysis of prescription drug utilization by a US managed care population (N=3119) of patients with a PD diagnosis and treatment with a PD medication.
REQUIP XL 24-hour provides a new level of convenience with once-daily dosing and simple titration
Long titration and dosing multiple times per day are strong factors for noncompliance with PD medications • Noncompliance may lead to suboptimal efficacy, premature treatment modifications, increased symptoms, and poor outcomes
Treatment strategies that simplify PD dosing–shorter titrations, reducing the number of doses per day, lower pill burdens–may improve adherence and result in better symptom control
AN INSTANT CONVERSION
4
Convert patients overnight from REQUIP IR to REQUIP XL 24-hour
A SIMPLE START
The 4-week Sample Kit provides a convenient, easy way to get patients started on REQUIP XL 24-hour
24
ONCE DAILY
Co n ion n ym veni rat osi t i e t d pt ple om nt once ily -daily dosing • Sim e-da atic ve nc treat ni en ment • Convenient o to nc e -d aily dosi ng • S imple titration
im
HOUR
•S
trat ion
ler to
24
g
ple ti
nd ty a safe Proven
One Dose Makes the Day n ve Pro
es
ab • With NEW REQUIP XL 24-hour, ilit nt e yp m tiv the first and only once-daily rofi eat ffec r le • t tic Effecti Pro •E dopamine agonist for Parkinson’s ve symptoma sa ven file o r fe s p a on fety and tolerability disease, patients can take their dose ty •C an t dt and get on with their day. en ole atm rab e r t ility atic profil e • Effective symptom • The only once-a-day oral DA • Simple titration • Significant reduction in “off” time within 2 weeks • Proven safety and tolerability
In the treatment of Parkinson’s disease…
Monotherapy for Patients With Early Parkinson’s Disease
Compliance Leads to Control
NEW Once-Daily REQUIP XL 24-hour Controls PD Signs and Symptoms as Effectively as Immediate-Release Ropinirole
CASE PROFILE—GLEN, CONCERNED ABOUT PILL BURDEN
Adjusted Mean Change From Baseline in UPDRS Total Motor Score (Part III) Prior to Formulation Switch at Week 20 (LOCF)
• 65 years of age; Hoehn and Yahr stage I • Newly diagnosed (no previous therapy) • Recently retired; physically active
REQUIP XL 24-hour
• Currently takes once-daily hypertension Adjusted Mean Change From Period Baseline
and cholesterol medications • Prefers simplicity of once-daily
medications; concerned about dosing multiple times a day
TREATMENT STRATEGY
IR Ropinirole
0
STARTED ON ONCE-DAILY REQUIP XL 24-HOUR USING THE 4-WEEK SAMPLE KIT
P=0.0582
-2 -4 -6 -8 -10
-10.6
-8.8
-12
• Doses of REQUIP XL 24-hour could be increased more quickly
than IR doses, resulting in an earlier response on UPDRS motor and CGI-I scores Dosing multiple times per day and long dosing titration may lead to noncompliance with PD medications
1 in 3
PD patients noncompliant at 1 year
• In a study of PD patients, the rate of noncompliance with
PD medications was high—and increased over time* —32% at 12 months
—43% at 24 months
—50% at 36 months
—57% at 48 months
* Retrospective analysis of prescription drug utilization by a US managed care population (N=3119) of patients with a PD diagnosis and treatment with a PD medication.
Treatment strategies that simplify PD dosing—shorter titrations, reducing the number of doses per day, lower pill burdens—may improve compliance and result in better symptom control
Patients were able to start on a higher dose and titrate faster with REQUIP XL 24-hour than with IR ropinirole—without added side effects
Dosing Simplicity Leads to Compliance REQUIP XL 24-hour provides a new level of convenience with once-daily dosing and simple titration
AN INSTANT CONVERSION
4
Convert patients overnight from REQUIP IR to REQUIP XL 24-hour
A SIMPLE START
The 4-week Sample Kit provides a convenient, easy way to get patients started on REQUIP XL 24-hour